Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Quay Adds Equipment, GMP Compliance

May 19, 2011 10:44 am | News | Comments

Quay Pharmaceuticals has invested in a variety of new equipment as part of its move to its purpose-designed facility in Deeside, U.K., which was officially opened last year.


Pharmatek Adds Spray Drying to Development Services

May 19, 2011 10:41 am | News | Comments

Pharmatek Laboratories, Inc. has added spray drying to its drug formulation and manufacturing capabilities, purchasing a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture.


ERT Awarded over $10 Million of ePRO Business

May 19, 2011 10:36 am | News | Comments

ERT has signed three contracts with pharmaceutical companies for its electronic patient reported outcomes (ePRO) business , totaling over $10 million.


DaVita Clinical Research Opens Cleanroom

May 19, 2011 10:31 am | News | Comments

DaVita Clinical Research has completed a Phase I-IIa cleanroom to comply with USP 797 high risk regulations demonstrating the cleanroom meets the requirements to handle compounds in a safe and efficient manner.


PPD Expands Product Development Consulting Services

May 19, 2011 10:27 am | News | Comments

PPD, Inc. announced it has established four practice areas through PPD Consulting-biosimilars, adaptive trial design, China regulatory strategy, and cardiovascular outcomes studies.


Ockham Appoints Vice-President of Preclinical and Regulatory Affairs

May 19, 2011 10:23 am | News | Comments

Harman Dubé has joined Ockham as vice-president of pre-clinical and regulatory affairs within the OckhamCRO division.


ERT Appoints New President and CEO

May 19, 2011 10:19 am | News | Comments

ERT, appointed Jeffrey S. Litwin, MD as its new president and chief executive officer and as a member of the board.


Almac Names New Vice President

May 19, 2011 10:01 am | News | Comments

Kole has joined Almac’s Clinical Technologies business unit as vice president of Clinical Project Services (CPS) and a member of the executive leadership team.


Genentech to Present on Various Therapies at ASCO

May 19, 2011 7:14 am | News | Comments

Genentech reported that data showing new personalized approaches for skin and lung cancer patients, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7.


Enrollment for Allon Clinical Trial Hits Halfway Mark

May 19, 2011 7:09 am | News | Comments

Allon Therapeutics Inc. has updated the progress of a Phase 2/3 clinical trial that is evaluating the company's lead neuroprotective drug candidate, davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.


Japan's Takeda Buying Nycomed for $13.6 Billion

May 19, 2011 6:19 am | by Tomoko A. Hosaka, Associated Press | News | Comments

Takeda Pharmaceutical Co. said it will buy Switzerland's Nycomed for $13.6 billion, in an all-cash deal that is the largest ever overseas takeover by a Japanese pharmaceutical company.


inVentiv Health to Acquire PharmaNet

May 19, 2011 6:14 am | News | Comments

inVentiv Health announced it has signed a definitive agreement to purchase PharmaNet Development Group, extending its global presence to nearly 40 countries and enhancing both its early- and late-stage clinical development capabilities.


Antibody Microarray

May 19, 2011 5:53 am | Drug Discovery & Development | Product Releases | Comments

The QuantiPlasma Array, a monoclonal antibody microarray from Randox Pharma Services, is designed to assess the level of multiple proteins simultaneously in human plasma.


argen-x Initiates Second Preclinical Program

May 19, 2011 5:49 am | News | Comments

arGEN-X announced that  ARGX-110, a human antibody specific for an undisclosed, clinically validated cell surface receptor has moved into formal pre-clinical development, less than 18 months since beginning its operations. 


SuppreMol Licenses Interleukin 3 Antibody

May 19, 2011 5:46 am | News | Comments

SuppreMol GmbH, a biopharmaceutical company developing therapeutics for the treatment of autoimmune diseases, has agreed to in-license an antibody directed against interleukin 3 (IL-3).



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.